Overview

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan compared with irinotecan alone as second-line therapy following treatment with a fluoropyrimidine and oxaliplatin based, non-irinotecan-containing regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company
ImClone LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

Camptothecin
Cetuximab
Irinotecan